急性リンパ性-リンパ芽球性白血病治療の世界市場レポート 2025年

急性リンパ性-リンパ芽球性白血病治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.5％で37億4,000万米ドルに成長します。予測期間の成長は、個別化医療へのアプローチ、新規薬剤へのアクセス拡大、世界ヘルスイニシアチブ、患者擁護と意識向上、規制経路の合理化などに起因すると考えられます。予測期間中の主な動向には、支持療法の革新、共同研究の取り組み、診断の革新、car-t細胞療法、生物製剤の革新などが含まれます。

遺伝的疾患の有病率の増加は、将来的に急性リンパ性リンパ芽球性白血病（ALL）治療薬市場の成長を促進すると予想されます。遺伝子疾患とは、個人のDNAや遺伝子の変化（変異）によって引き起こされる医学的問題です。時間の経過とともに遺伝子変異は細胞内に蓄積し、過剰な変異を持つ細胞は正常に機能しなくなり、制御不能に増殖し、がん化する可能性があります。遺伝子検査は、急性リンパ性リンパ芽球性白血病患者の特定の遺伝子異常を特定するために治療的に用いられ、治療方針の決定に役立ちます。例えば、米国を拠点とする非営利団体Cystic Fibrosis Foundationは2023年、肺移植を受けなかった嚢胞性線維症の総人口が、2022年の31,171人から2023年には31,752人に増加したと報告しています。このように、遺伝的疾患の有病率の上昇が、急性リンパ性リンパ芽球性白血病（ALL）治療薬市場の成長に拍車をかけています。

骨髄移植に対する需要の高まりは、今後の急性リンパ性-リンパ芽球性白血病治療市場の成長を後押しすると予想されます。骨髄移植は、損傷した骨髄や病気の骨髄を健康な造血幹細胞と置き換える医療処置です。この方法は、急性リンパ性リンパ芽球性白血病において、高い寛解率、症状の軽減、微小残存病変（MRD）の根絶、治癒の可能性など、いくつかの潜在的な利点をもたらします。例えば、2023年6月、保健資源サービス庁は、骨髄ドナー登録者数が2021年の9,285,029人から2022年には9,475,534人に増加したと報告しました。その結果、骨髄移植の需要の増加が急性リンパ性-リンパ芽球性白血病治療市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の急性リンパ性-リンパ芽球性白血病治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の急性リンパ性-リンパ芽球性白血病治療市場：成長率分析
• 世界の急性リンパ性-リンパ芽球性白血病治療市場の実績：規模と成長, 2019-2024
• 世界の急性リンパ性-リンパ芽球性白血病治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の急性リンパ性-リンパ芽球性白血病治療：総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性リンパ性-リンパ芽球性白血病治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• 放射線治療
• 幹細胞移植
• 世界の急性リンパ性-リンパ芽球性白血病治療市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生検と骨髄穿刺
• 完全血球計算（CBC）と白血球分類
• フィラデルフィア染色体の存在
• 脊髄穿刺と脳脊髄液（CSF）分析
• 免疫表現型解析またはフローサイトメトリーによる表現型解析
• ポリメラーゼ連鎖反応（PCR）
• 世界の急性リンパ性-リンパ芽球性白血病治療市場細胞の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フィラデルフィア染色体
• 前駆B細胞急性リンパ性白血病（ALL）
• T細胞急性リンパ性白血病（ALL）
• 世界の急性リンパ性-リンパ芽球性白血病治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の急性リンパ性-リンパ芽球性白血病治療市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 大人
• 世界の急性リンパ性-リンパ芽球性白血病治療市場化学療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 導入化学療法
• 強化化学療法
• 維持化学療法
• 世界の急性リンパ性-リンパ芽球性白血病治療市場、標的療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤
• モノクローナル抗体
• 世界の急性リンパ性-リンパ芽球性白血病治療市場、放射線治療の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 頭蓋放射線療法
• 全身照射
• 世界の急性リンパ性-リンパ芽球性白血病治療市場幹細胞移植の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家幹細胞移植
• 同種幹細胞移植

第7章 地域別・国別分析

• 世界の急性リンパ性-リンパ芽球性白血病治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性リンパ性-リンパ芽球性白血病治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性リンパ性-リンパ芽球性白血病治療市場：競合情勢
• 急性リンパ性-リンパ芽球性白血病治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Amgen Inc.
• Baxter International Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Jazz Pharmaceuticals Inc.
• Ono Pharmaceutical Co. Ltd.
• Genmab A/S
• Kite Pharma
• ADC Therapeutics
• Kiadis Pharma
• SymBio Pharmaceuticals Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性リンパ性-リンパ芽球性白血病治療市場2029：新たな機会を提供する国
• 急性リンパ性-リンパ芽球性白血病治療市場2029：新たな機会を提供するセグメント
• 急性リンパ性-リンパ芽球性白血病治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leukemia, is a rapidly progressing cancer that originates in the bone marrow, where blood cells are produced. It predominantly affects immature white blood cells called lymphocytes, which play a crucial role in the body's immune system.

The primary therapeutic modalities for acute lymphocytic-lymphoblastic leukemia include chemotherapy, targeted therapy, radiation therapy, and stem cell transplantation. Chemotherapy is a systemic treatment that utilizes drugs to destroy or inhibit the growth of rapidly dividing cells, including cancer cells. The diagnostic procedures for ALL involve various tests such as biopsy and bone marrow aspiration, complete blood count (CBC) and differential, assessment for the presence of the Philadelphia chromosome, spinal tap and cerebrospinal fluid (CSF) analysis, and immunophenotyping or phenotyping by flow cytometry. Additionally, molecular diagnostic techniques such as polymerase chain reaction (PCR) are used. Acute lymphocytic-lymphoblastic leukemia can be diagnosed in various cell types, including the Philadelphia chromosome, precursor B-cell ALL, and T-cell ALL. The administration routes for treatment include oral and parenteral, catering to both pediatric and adult age groups.

The acute lymphocytic-lymphoblastic leukemia therapeutics market research report is one of a series of new reports from The Business Research Company that provides acute lymphocytic-lymphoblastic leukemia therapeutics market statistics, including acute lymphocytic-lymphoblastic leukemia therapeutics industry global market size, regional shares, competitors with an acute lymphocytic-lymphoblastic leukemia therapeutics market share, detailed acute lymphocytic-lymphoblastic leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the acute lymphocytic-lymphoblastic leukemia therapeutics industry. This acute lymphocytic-lymphoblastic leukemia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute lymphocytic-lymphoblastic leukemia therapeutics market size has grown strongly in recent years. It will grow from $2.85 billion in 2024 to $3.02 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to chemotherapy advancements, biological and targeted therapies, pediatric oncology research, improved supportive care, stem cell transplantation.

The acute lymphocytic-lymphoblastic leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.74 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to personalized medicine approaches, expanded access to novel agents, global health initiatives, patient advocacy and awareness, regulatory pathway streamlining. Major trends in the forecast period include supportive care innovation, collaborative research efforts, diagnostic innovations, car-t cell therapies, innovations in biologics.

The increasing prevalence of genetic conditions is anticipated to drive the growth of the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market in the future. Genetic conditions are medical issues caused by alterations (mutations) in an individual's DNA or genes. Over time, gene mutations can accumulate in cells, and cells with excessive mutations may cease to function normally, proliferate uncontrollably, and become cancerous. Genetic testing is employed therapeutically to identify specific genetic abnormalities in individuals with acute lymphocytic-lymphoblastic leukemia, which can help guide treatment decisions. For instance, in 2023, the Cystic Fibrosis Foundation, a US-based non-profit organization, reported that the total population with cystic fibrosis who did not undergo lung transplantation increased from 31,171 in 2022 to 31,752 in 2023. Thus, the rising prevalence of genetic conditions is fueling the growth of the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market.

The growing demand for bone marrow transplantation is expected to boost the growth of the acute lymphocytic-lymphoblastic leukemia therapeutics market in the future. Bone marrow transplantation is a medical procedure that involves replacing damaged or diseased bone marrow with healthy hematopoietic stem cells. This procedure offers several potential advantages in acute lymphocytic-lymphoblastic leukemia, including higher remission rates, reduced symptoms, eradication of minimal residual disease (MRD), and the possibility of a cure. For example, in June 2023, the Health Resources and Services Administration reported that the number of registered bone marrow donors rose from 9,285,029 in 2021 to 9,475,534 in 2022. Consequently, the increasing demand for bone marrow transplantation is propelling the growth of the acute lymphocytic-lymphoblastic leukemia therapeutics market.

Major companies within the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market are developing innovative therapies, such as Tecartus (brexucabtagene autoleucel), by utilizing chimeric antigen receptor (CAR) T-cell therapy and obtaining approvals to better address the needs of their current consumers. CAR T-cell therapy is a form of immunotherapy that employs a patient's own T cells to combat cancer. For example, in July 2024, Janssen Research & Development LLC, a US-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA), a federal agency, for its daratumumab and hyaluronidase-fish in combination with bortezomib, lenalidomide, and dexamethasone for the induction and consolidation of multiple myeloma in patients undergoing autologous stem cell transplantation (ASCT).

In February 2024, BioNTech SE, a biotechnology company based in Germany, partnered with Autolus Ltd. This collaboration enables both companies to access manufacturing and commercial infrastructure as well as technology to advance their autologous CAR-T cell therapy program. Autolus Ltd. is a biotechnology company located in the UK.

Major companies operating in the acute lymphocytic-lymphoblastic leukemia therapeutics market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Astellas Pharma Inc., Eisai Co. Ltd., Jazz Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Genmab A/S, Kite Pharma, ADC Therapeutics, Kiadis Pharma, SymBio Pharmaceuticals Limited, Celyad Oncology SA, Precigen Inc., Leadiant Biosciences Inc., Medexus Pharma Inc., Spectrum Pharmaceuticals Inc., OBI Pharma Inc.

North America was the largest region in the acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lymphocytic-lymphoblastic leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the acute lymphocytic-lymphoblastic leukemia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The acute lymphocytic-lymphoblastic leukemia (ALL) therapeutics market includes revenues earned by entities by providing services such as laboratory testing, molecular diagnostics, chemotherapy administration, targeted therapy, blood and platelet transfusions, and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market also includes sales of Arranon (nelarabine), Asparaginase erwinia chrysanthemi, Asparlas (calaspargase pegol-mknl), Besponsa (inotuzumab ozogamicin), and Blincyto (blinatumomab). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute lymphocytic-lymphoblastic leukemia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute lymphocytic-lymphoblastic leukemia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute lymphocytic-lymphoblastic leukemia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy Type: Chemotherapy; Targeted Therapy; Radiation Therapy; Stem Cell Transplantation
• 2) By Diagnosis: Biopsy And Bone Marrow Aspiration; Complete Blood Count (CBC) And Differential; Presence Of Philadelphia Chromosome; Spinal Tap And Cerebrospinal Fluid (CSF) Analysis; Immunophenotyping Or Phenotyping By Flow Cytometry; Polymerase Chain Reaction (PCR)
• 3) By Cell Type: Philadelphia Chromosome; Precursor B-Cell Acute Lymphoblastic Leukemia (ALL); T-Cell Acute Lymphoblastic Leukemia (ALL)
• 4) By Route Of Administration: Oral; Parenteral
• 5) By Age Group: Pediatrics; Adults
• Subsegments:
• 1) By Chemotherapy: Induction Chemotherapy; Consolidation Chemotherapy; Maintenance Chemotherapy
• 2) By Targeted Therapy: Tyrosine Kinase Inhibitors; Monoclonal Antibodies
• 3) By Radiation Therapy: Cranial Radiation Therapy; Total Body Irradiation
• 4) By Stem Cell Transplantation: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Characteristics

3. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Trends And Strategies

4. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Growth Rate Analysis
• 5.4. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Total Addressable Market (TAM)

6. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Segmentation

• 6.1. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Stem Cell Transplantation
• 6.2. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy And Bone Marrow Aspiration
• Complete Blood Count (CBC) And Differential
• Presence Of Philadelphia Chromosome
• Spinal Tap And Cerebrospinal Fluid (CSF) Analysis
• Immunophenotyping Or Phenotyping By Flow Cytometry
• Polymerase Chain Reaction (PCR)
• 6.3. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Philadelphia Chromosome
• Precursor B-Cell Acute Lymphoblastic Leukemia (ALL)
• T-Cell Acute Lymphoblastic Leukemia (ALL)
• 6.4. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.5. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatrics
• Adults
• 6.6. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Induction Chemotherapy
• Consolidation Chemotherapy
• Maintenance Chemotherapy
• 6.7. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors
• Monoclonal Antibodies
• 6.8. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cranial Radiation Therapy
• Total Body Irradiation
• 6.9. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Sub-Segmentation Of Stem Cell Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Transplant
• Allogeneic Stem Cell Transplant

7. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Regional And Country Analysis

• 7.1. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 8.1. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 9.1. China Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 9.2. China Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 10.1. India Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 11.1. Japan Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 11.2. Japan Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 12.1. Australia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 13.1. Indonesia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 14.1. South Korea Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 14.2. South Korea Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 15.1. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 15.2. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 16.1. UK Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 17.1. Germany Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 18.1. France Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 19.1. Italy Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 20.1. Spain Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 21.1. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 21.2. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 22.1. Russia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 23.1. North America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 23.2. North America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 24.1. USA Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 24.2. USA Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 25.1. Canada Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 25.2. Canada Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 26.1. South America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 26.2. South America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 27.1. Brazil Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 28.1. Middle East Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 28.2. Middle East Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

• 29.1. Africa Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Overview
• 29.2. Africa Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Competitive Landscape
• 30.2. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Gilead Sciences Inc.
• 31.5. Amgen Inc.
• 31.6. Baxter International Inc.
• 31.7. Astellas Pharma Inc.
• 31.8. Eisai Co. Ltd.
• 31.9. Jazz Pharmaceuticals Inc.
• 31.10. Ono Pharmaceutical Co. Ltd.
• 31.11. Genmab A/S
• 31.12. Kite Pharma
• 31.13. ADC Therapeutics
• 31.14. Kiadis Pharma
• 31.15. SymBio Pharmaceuticals Limited

32. Global Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

34. Recent Developments In The Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market

35. Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer